RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Cash and cash equivalents

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 20244,572-55.92%
Dec 31, 202310,372-1.33%
Dec 31, 202210,512+54.59%
Dec 31, 20216,800+13.55%
Dec 31, 20205,989+91.91%
Dec 31, 20193,121+17.40%
Dec 31, 20182,658+59.62%
Dec 31, 20171,665+40.67%
Dec 31, 20161,184+65.64%
Dec 31, 2015715+14.32%
Dec 31, 2014625+9.83%
Dec 31, 2013569+16.32%
Dec 31, 2012489+2.96%
Dec 31, 2011475+95.45%
Dec 31, 2010243

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)